You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GEMOX

Showing 1 - 25 of 145
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gallbladder Cancer Trial (Envafolimab+Gemox)

Not yet recruiting
  • Gallbladder Cancer
  • (no location specified)
Aug 25, 2023

Combined Hepatocellular Cholangiocarcinoma Trial (gemcitabine ,oxaliplatin,anlotinib,Sintilimab)

Not yet recruiting
  • Combined Hepatocellular Cholangiocarcinoma
  • gemcitabine ,oxaliplatin,anlotinib,Sintilimab
  • (no location specified)
Sep 10, 2023

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer Trial in Tianjin

Recruiting
  • Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Nov 16, 2022

Unresectable Gallbladder Cancer Trial in Guangzhou (Carrilizumab plus GEMOX)

Not yet recruiting
  • Unresectable Gallbladder Cancer
  • Carrilizumab plus GEMOX
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jun 16, 2023

Biliary Tract Carcinoma Trial in Shanghai (Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab)

Recruiting
  • Biliary Tract Carcinoma
  • Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 25, 2022

Intrahepatic Cholangiocarcinoma Trial in Tianjin (Sintilimab, IBI305, GEMOX)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Feb 22, 2022

Perihilar Cholangiocarcinoma Trial in Guangzhou (PD-1antibody plus GEMOX)

Not yet recruiting
  • Perihilar Cholangiocarcinoma
  • PD-1antibody plus GEMOX
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2022

DLBCL Trial in China (Orelabrutinib and Gemox)

Not yet recruiting
  • DLBCL
  • Orelabrutinib and Gemox
  • Chongqing, Chongqing, China
  • +7 more
Jul 5, 2022

DLBCL, Not Otherwise Specified Trial in Chongqing (selinexor)

Recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 27, 2023

Gallbladder Carcinoma Trial in Shanghai (gemcitabine and oxaliplatin., Afatinib)

Recruiting
  • Gallbladder Carcinoma
  • Shanghai, Shanghai, China
  • +1 more
Dec 21, 2022

Cholangiocarcinoma Trial in Tianjin (GEMOX Regimen, Lenvatinib, Toripalimab)

Recruiting
  • Cholangiocarcinoma
  • GEMOX Regimen
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Jan 28, 2022

Intrahepatic Cholangiocarcinoma Trial in Hangzhou (Tislelizumab combined with GEMOX (GOT) regimen)

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Tislelizumab combined with GEMOX (GOT) regimen
  • Hangzhou, Zhejiang, China
    1# Banshan East Rd. Zhejiang cancer hospital
Sep 24, 2022

Biliary Tract Cancer, PD-1 Antibody, Gemox Trial in Shanghai (PD-1+Lenvatinib+GEMOX)

Recruiting
  • Biliary Tract Cancer
  • +3 more
  • Shanghai, China
    Zhongshan hospital
Dec 11, 2021

Advanced Biliary Tract Carcinoma Trial in Hangzhou (Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur)

Not yet recruiting
  • Advanced Biliary Tract Carcinoma
  • Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur
  • Hangzhou, Zhejiang, China
    the First Affiliated Hospital, School of Medicine, Zhejiang Univ
Jul 6, 2022

Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma Trial in Zhengzhou, Nanjing (SHR-1210, Apatinib, FOLFOX4)

Active, not recruiting
  • Advanced Primary Liver Cancer
  • Advanced Biliary Tract Carcinoma
  • SHR-1210
  • +3 more
  • Zhengzhou, Henan, China
  • +1 more
Apr 26, 2022

Biliary Tract Cancer, Cholangiocarcinoma Trial in Nanjing (SHR-1210+GEMOX)

Completed
  • Biliary Tract Cancer
  • Cholangiocarcinoma
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Oct 27, 2021

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System Trial (Tislelizumab)

Not yet recruiting
  • Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
  • (no location specified)
Sep 6, 2021

Gallbladder Cancer Trial in Varanasi (Everolimus 10 mg, Standard of care)

Recruiting
  • Gallbladder Cancer
  • Everolimus 10 mg
  • Standard of care
  • Varanasi, UP, India
    Banaras Hindu University
Apr 18, 2023

Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Lenvatinib combined with gemox, Toripalimab combined with lenvatinib)

Active, not recruiting
  • Cholangiocarcinoma, Intrahepatic
  • Lenvatinib combined with gemox
  • Toripalimab combined with lenvatinib
  • Shanghai, China
  • +1 more
Jul 5, 2021

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Gemox combimed PD1 antibody)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Gemox combimed PD1 antibody
  • Shanghai, Shanghai, China
    Zhongshan hospital
Jul 7, 2021

Lymphoma, Large B-Cell, Diffuse, Tumors by Histologic Type Trial in China (penpulimab, lenalidomide, Rituximab, Gemcitabine,

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Neoplasms by Histologic Type
  • penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
  • Hefei, Anhui, China
  • +3 more
Mar 3, 2022

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022

Biliary Tract Carcinoma Trial in Shanghai (Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab)

Recruiting
  • Biliary Tract Carcinoma
  • Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 5, 2021

Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib Trial in Shanghai (Neoadjuvant treatment)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • +3 more
  • Neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
Jul 5, 2021

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Guangzhou (pegaspargase, Gemcitabine, Oxaliplatin)

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 12, 2021